LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Compugen Ltd

Open

1.72 2.99

Overview

Share price change

24h

Current

Min

1.63

Max

1.77

Key metrics

By Trading Economics

Income

-1.1M

-7.2M

Sales

813K

2.3M

P/E

Sector Avg

60.333

51.198

EPS

-0.08

Profit margin

-314.405

Employees

74

EBITDA

-12M

-7.5M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+309.36% upside

Dividends

By Dow Jones

Next Earnings

5 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-546M

140M

Previous open

-1.27

Previous close

1.72

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Compugen Ltd Chart

Past performance is not a reliable indicator of future results.

Related News

5 Jun 2025, 20:45 UTC

Earnings

Broadcom 2Q Sales Climb on Booming AI Demand

5 Jun 2025, 23:45 UTC

Market Talk

Nikkei May Decline as Caution Over U.S. Economy Continues -- Market Talk

5 Jun 2025, 23:44 UTC

Market Talk

Gold Edges Higher on Weak U.S. Data -- Market Talk

5 Jun 2025, 23:30 UTC

Market Talk

NZME Cost Cuts Can Cushion Effect of Weak Market -- Market Talk

5 Jun 2025, 21:32 UTC

Earnings

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 Jun 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

5 Jun 2025, 20:45 UTC

Earnings

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 Jun 2025, 20:24 UTC

Earnings

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Cont Ops EPS $1.03 >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Rev $15B >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Net $4.97B >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Adj EPS $1.58 >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q EPS $1.03 >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom Sees 3Q Rev $15.8B >AVGO

5 Jun 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy: Transaction Is Expected to Close in the 4Q >CEG

5 Jun 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy: Calpine Deal Clears Texas Regulatory Review

5 Jun 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy: With Approval From PUCT Secured, Transaction Awaits Clearance From NY State Public Service Commission, Federal Energy Regulatory Commission and DOJ >CEG

5 Jun 2025, 19:22 UTC

Market Talk

Oil Futures Resume Upward Moves -- Market Talk

5 Jun 2025, 19:00 UTC

Market Talk

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

5 Jun 2025, 18:32 UTC

Market Talk

Gold Slips After Trump-Xi Call -- Market Talk

5 Jun 2025, 18:26 UTC

Earnings

These Stocks Are Moving the Most Today: Broadcom, Tesla, Circle, Brown-Forman, MongoDB, Planet Labs, ChargePoint, Ciena, and More -- Barrons.com

5 Jun 2025, 18:06 UTC

Market Talk

Transpacific Ship Freight Rates Spike on China Tariff Truce -- Market Talk

5 Jun 2025, 16:30 UTC

Acquisitions, Mergers, Takeovers

Vallourec Completes The Acquisition Of Thermotite Do Brasil >VK.FR

5 Jun 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

5 Jun 2025, 16:18 UTC

Market Talk

U.S. Natural Gas Market Shrugs Off Big Storage Build -- Market Talk

5 Jun 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 Jun 2025, 16:12 UTC

Market Talk

Global Energy Roundup: Market Talk

5 Jun 2025, 16:12 UTC

Market Talk

Copper Prices Rise on Positive Signals From Trump on China Trade Talks -- Market Talk

5 Jun 2025, 16:03 UTC

Market Talk

U.S. Diesel, Gasoline Futures Pick Back Up -- Market Talk

5 Jun 2025, 15:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Compugen Ltd Forecast

Price Target

By TipRanks

309.36% upside

12 Months Forecast

Average 7 USD  309.36%

High 10 USD

Low 4 USD

Based on 3 Wall Street analysts offering 12 month price targets forCompugen Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

1.25 / 1.48Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.